US drug firms' reputation improves

21 May 2006

The reputation of the US drug industry has shown significant improvement for a second year in succession. Never-theless, the public perception of the industry remains poor. Every year, Harris Interactive measures public opinion concerning approximately 20 industries, specifically asking if respondents believe that the industry is doing a "good job" or a "bad job" of serving their customers.

In 2006, the survey covered 21 industries, supermarkets coming top (91% approval) and the tobacco industry at the bottom (34% approval). The drug industry in net approval terms - the difference between respondents saying that the industry did a "good" and a "bad" job - has declined since 1997 from +60% to +25%. However the low-point was reached in 2004 with a score of -4% that year. For 2005 the rating was +13%. Harris Interactive rated drug firms' public approval as "the most volatile of any industry."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight